Skip to Content

EHA24: How I Treat Relapsed/Refractory Multiple Myeloma in Early Lines

Fredrik Schjesvold, Head of Oslo Myeloma Center, discusses his upcoming talk at EHA 2024 in Madrid about selecting second-line treatments for myeloma after the first relapse. He emphasizes considering overall survival and progression-free survival data, changing the mechanism of action, and the potential future impact of new drug combinations on treatment choices.

Fredrik Schjesvold

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top